Penciclovir

證據等級: L5

預測適應症: 10 個

Penciclovir: From Herpes Simplex Virus Infections to Fascioliasis

One-Sentence Summary

Penciclovir is a guanine nucleoside analogue antiviral, pharmacologically used against herpes simplex virus (HSV) infections by requiring viral thymidine kinase (TK) for activation. The TxGNN model predicts it may be effective for Fascioliasis (liver fluke infection), with a prediction score of 99.06%, but currently no clinical trials and no published literature support this direction, and the model’s own mechanistic rationale argues against biological plausibility.

Quick Overview

Item	Content
Original Indication	Herpes simplex virus (HSV) infections (mechanism inferred from evidence pack rationale; structured indication registry data not available — see note below)
Predicted New Indication	Fascioliasis
TxGNN Prediction Score	99.06%
Evidence Level	L5
Denmark Market Status	Not marketed
Number of Marketing Authorisations	0
Recommended Decision	Hold

Note on Original Indication: The evidence pack’s original_indications and taiwan_regulatory.licenses fields are both empty, so no registry-sourced approved indication text is available. The indication above is inferred solely from the mechanistic description embedded in the evidence pack’s own repurposing rationale (guanine nucleoside analogue activated by viral thymidine kinase — the canonical Penciclovir/HSV mechanism). This should be verified against the official Summary of Product Characteristics (SmPC) before use in any decision document.

Why is This Prediction Reasonable?

Currently, detailed mechanism of action (MOA) data is flagged as a data gap ([Data Gap]) in the structured drug record. However, the evidence pack’s own repurposing rationale provides a partial mechanistic description: Penciclovir is a guanine nucleoside analogue whose antiviral activity depends on first-step phosphorylation by a viral-specific thymidine kinase (TK) — a mechanism specific to herpesviruses such as HSV.

Unlike a typical repurposing candidate, the mechanistic analysis included in this evidence pack does not support the predicted new indication. Fascioliasis is caused by the trematode Fasciola hepatica/gigantica (liver fluke), a helminth with no known viral-type TK-dependent activation pathway. The rationale explicitly states that there is “no known or hypothesized nucleoside-metabolism interference mechanism” supporting anti-helminthic activity for Penciclovir, and concludes that the high TxGNN similarity score is most likely driven by knowledge-graph embedding proximity (e.g., shared graph neighbors with other antiparasitic agents) rather than genuine pharmacological plausibility.

In other words, this is a case where the model’s quantitative score (99.06%) is high, but the qualitative mechanistic evidence — drawn from the same evidence pack — actively argues against clinical relevance. This combination (high score, contradicted mechanism, zero external evidence) is the primary basis for the “Hold” recommendation below.

Other Predicted Indications (Same Evidence Pack)

The evidence pack contains four additional distinct predicted indications for Penciclovir, all scored similarly high by TxGNN but likewise unsupported by clinical trials, literature, or a plausible mechanism:

Rank	Disease	TxGNN Score	Evidence Level	Recommendation	Mechanistic Note
3–4	Cysticercosis	98.99%	L5	Hold	No overlap with standard albendazole/praziquantel mechanisms (microtubule/calcium-channel targets)
5–6	Coenurosis	98.75%	L5	Hold	Same helminth-class reasoning as cysticercosis; likely graph-structural artifact
7–8	Intestinal helminthiasis	98.70%	L5	Hold	No published in vitro/in vivo anti-helminthic activity data for Penciclovir
9–10	Malignant pleural mesothelioma	98.51%	L5	Hold	Penciclovir’s kinase specificity is highly selective for HSV TK, with very low affinity for mammalian (including tumor) kinases; no cell-line or animal-model data support antiproliferative use

All five predictions share the same profile: no clinical trials, no literature, L5 evidence (model prediction only), and a mechanistic rationale that explicitly cautions against interpreting the score as pharmacologically meaningful.

Clinical Trial Evidence

Currently no related clinical trials registered.

(Query log confirms ClinicalTrials.gov and WHO ICTRP searches were performed for all five predicted diseases on 2026-03-24, with zero results.)

Literature Evidence

Currently no related literature available.

(Query log confirms PubMed searches were performed for all five predicted diseases on 2026-03-24, with zero results.)

Denmark Market Information

Penciclovir currently has no marketing authorisations on record in this evidence pack (total_licenses: 0, market status: Not marketed). No national (Laegemiddelstyrelsen) or centralised (EMA) authorisation details are available to list.

Safety Considerations

Please refer to the approved Summary of Product Characteristics (SmPC) for safety information.

Important: This evidence pack flags a Blocking data gap (DG001) — TFDA/label warnings and contraindications could not be retrieved, which by itself prevents progression to a formal safety (S1) evaluation. A drug interaction (DDI) query also returned no results (not_found), meaning absence of interactions should not be assumed — it reflects a data availability gap, not a confirmed clean interaction profile.

Conclusion and Next Steps

Decision: Hold

Rationale:

All five predicted indications rest on L5 evidence (model prediction only) with zero supporting clinical trials or literature.
The evidence pack’s own mechanistic analysis for the top-ranked prediction (fascioliasis) explicitly concludes the high similarity score likely reflects a knowledge-graph embedding artifact rather than genuine pharmacological plausibility — the same reasoning applies to the other four candidates.
A Blocking data gap (missing SmPC/label warnings and contraindications) prevents any safety pre-assessment (S1) regardless of efficacy evidence.
Penciclovir is not currently marketed in Denmark (0 marketing authorisations), so no local dosage form or approved-indication pathway currently exists to support even guardrail-based off-label use.

To proceed, the following is needed:

Retrieve the official SmPC / label warnings and contraindications (resolves DG001, Blocking)
Obtain confirmed mechanism of action (MOA) data from DrugBank or primary literature (resolves DG002, High)
Conduct or identify in vitro/in vivo studies testing Penciclovir against Fasciola, Taenia species, or mesothelioma cell lines before any further evidence-level upgrade is considered
Re-run clinical trial and literature searches periodically, as current searches (2026-03-24) returned zero hits for all five candidate indications
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.